Phase II trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell carcinoma of the head and neck (LA SCCHN): Feasibility and 2-year OS.

Thomas Kuhnt, Juergen Dunst, A. Pirnasch et al.|Journal of Clinical Oncology|2013

Cited by 3